Iloprost for idiopathic pulmonary arterial hypertension

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 2, 2005, Pages 215-223

  Leuchte, Hanno H ^a   Behr, Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aerosol; Idiopathic pulmonary arterial hypertension; Iloprost; Treatment

Indexed keywords

ADENOSINE; AMBRISENTAN; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIGOXIN; DIURETIC AGENT; ILOPROST; NITRIC OXIDE; OXYGEN; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; UNIPROST;

ANTIHYPERTENSIVE ACTIVITY; ARTHRALGIA; BONE PAIN; CLINICAL TRIAL; COUGHING; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INACTIVATION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; EYE DISEASE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; INJECTION PAIN; LEG PAIN; LIVER TOXICITY; LONG TERM CARE; OXYGEN THERAPY; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SYSTEMIC DISEASE; TERATOGENICITY;

CLINICAL TRIALS; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; VASODILATOR AGENTS;

EID: 15844367644     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.2.215     Document Type: Review

References (63)

1. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115, 343-349 (1991).
2. Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43, S5-S12 (2004).
3. Rubin LJ. Primary pulmonary hypertension. N. Engl. J. Med. 336, 111-117 (1997).
4. Olschewski H, Rose F, Gruning E et al. Cellular pathophysiology and therapy of pulmonary hypertension. J. Lab. Clin. Med. 138, 367-377 (2001).
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327, 76-81 (1992).
6. Sitbon O, Humbert M, Jagot JL et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium channel blockers in primary pulmonary hypertension. Eur. Respir. J. 12, 265-270 (1998).
7. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70, 580-587 (1984).
8. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334, 296-302 (1996).
9. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am. J. Respir. Crit. Care Med. 167, 580-586 (2003).
10. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132, 425-434 (2000).
11. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99, 1858-1865 (1999).
12. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63, 604-106 (1997).
13. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med. 162, 1846-1850 (2000).
14. Olschewski H, Rose F, Schermuly R et al. Prostacyclin and its analogs in the treatment of pulmonary hypertension. Pharmacol. Ther. 102, 139-153 (2004).
15. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. 121, 409-415 (1994).
16. Galie N, Humbert M, Vachiery J et al. Effects of beraprost sodium, an oral prostacyclin analog, in patients with pulmonary artery hypertension: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 39, 1496-1502 (2002).
17. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165, 800-804 (2002).
18. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322-329 (2002).
19. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 358, 1119-1123 (2001).
20. Sastry BKS, Narasimham C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. 43, 1149-1153 (2004).
21. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351, 1425-1436 (2004).
22. Barst RJ, McGoon M, McLaughlin V et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41, 2119-2125 (2003).
23. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002).
24. McLaughlin V, Sitbon O, Rubin LJ. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 167 (2003) (Abstract).
25. Barst RJ, Langleben D, Frost A et al. Sitaxsental therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169, 441-447 (2004).
26. Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-yeat follow-up study. Chest 126, 1377-1381 (2004).
27. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide and iloprost in primary pulmonary hypertension. Chest 125, 580-586 (2004).
28. Michelakis ED, Tymchak W, Noga M et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108, 2066-2069 (2003).
29. Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104, 1218-1222 (2001).
30. Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136, 515-522 (2002).
31. Pomeranz HD, Smith KH, Hart J, Egan RA, Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 109, 584-587 (2002).
32. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic amp generation in human pulmonary artery. Am. J. Respir. Cell. Mol. Biol. 26, 194-201 (2002).
33. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol. Rev. 79, 1193-1226 (1999).
34. Turcato S, Clapp LH. Effects of the adenyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclin AMP elevation in isolated guinea-pig aorta. Br. J. Pharmacol. 126, 845-847 (1999).
35. + channels play a major role in mediating the vascular effects of iloprost and cicaprost. Eur. J. Pharmacol. 356, 215-224 (1998).
36. Rose F, Hattar K, Gakisch S et al. Increased neutrophil mediator release in patients with pulmonary hypertension - suppression by inhaled iloprost. Thromb. Haemostas. 90, 1141-1149 (2003).
37. Beghetti M, Reber G, de Moerloose P et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur. Respir. J. 19, 518-524 (2002).
38. Schermuly RT, Kreisselmeier KP, Ghofrani HA et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ. Res. 94, 1101-1108 (2004).
39. Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur. Respir. J. 20, 339-343 (2002).
40. Ewert R, Opitz C, Wensel R et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z. Kardiol. 89, 987-999 (2000).
41. Olschewski H, Ghofrani HA, Walmrath D et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 160, 600-607 (1999).
42. Ghofrani HA, Friese G, Discher T et al Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur. Respir. J. 23, 321-326 (2004).
43. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med. 124, 820-824 (1996).
44. Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med. 24, 631-634 (1998).
45. Olschewski H, Ghofrani HA, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann. Intern. Med. 132, 435-443 (2000).
46. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analog iloprost in man. Eur. J. Clin Pharmacol. 30, 61-8 (1986).
47. Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol. 35, 176-182 (2000).
48. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolized prostacyclin in adult respiratory distress syndrome. Lancet 342, 961-962 (1993).
49. Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur. Respir. J. 10, 1084-1092 (1997).
50. Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, earosolized by three different devices, in severe pulmonary hypertension. Chest 124, 1294-1304 (2003).
51. Gessler T, Schmehl T, Hoeper MM et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J. 17, 14-19 (2001).
52. Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am. J. Respir. Crit. Care Med. 151, 724-730 (1995).
53. 2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 154, 1671-1677 (1996).
54. Hoeper MM, Schwarze M, Ehlerding S. et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analog. N. Engl. J. Med. 342, 1866-1870 (2000).
55. Olschewski H, Nikkho S, Behr J et al. Long-term survival in patients with pulmonary hypertension inhaling iloprost. European Society of Cardiology Congress. Vienna, Austria, 30 August-3 September 2000 (Abstract 2567).
56. Sitbon O, Humbert M, Ioos V et al. Who benefits from long-term calcium channel-blocker therapy in primary pulmonary hypertension? Am. J. Respir. Crit. Care Med. (2003)(Abstract A440).
57. Vachiery JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from iv. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 121, 1561-1565 (2002).
58. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42, 158-164 (2003).
59. Humbert M, Barst RJ, Robbins IM et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 24, 353-359 (2004).
60. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 24, 1007-1010 (2004).
61. Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102, 865-870 (2000).
62. Leuchte HH, Holzapfel M, Baumgartner RA et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J. Am. Coll. Cardiol. 43, 764-770 (2004).
63. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, S81-S88 (2004).